Nomograms for preoperative prediction of axillary nodal status in breast cancer. BJS 2017; 104: 1494-1505.
Published: 18th July 2017
Authors: L. Dihge, P.‐O. Bendahl, L. Rydén
Axillary staging in patients with breast cancer and clinically node‐negative disease is performed by sentinel node biopsy (
Patients presenting to Skåne University Hospital, Lund, with breast cancer were included in a prospectively maintained registry between January 2009 and December 2012. Those with a preoperative diagnosis of nodal metastases were excluded. Patients with data on hormone receptor status, human epidermal growth factor receptor 2 and Ki‐67 expression were included to allow grouping into surrogate molecular subtypes. Based on logistic regression analyses, nomograms summarizing the strength of the associations between the predictors and each nodal status endpoint were developed. Predictive performance was assessed using the area under the receiver operating characteristic (
Of the 692 patients eligible for analysis, 248 were diagnosed with node‐positive disease. Molecular subtype, age, mode of detection, tumour size, multifocality and vascular invasion were identified as predictors of any nodal disease. Nomograms that included these predictors demonstrated good predictive abilities, and comparable performances in the internal validation; the area under the
The nomograms presented facilitate preoperative decision‐making regarding the extent of axillary surgery.Read more
You may also be interested in
Authors: Z. E. Winters, J. R. Benson
Authors: L. Feinberg, A. Srinivasan, J. K. Singh, M. Parry, J. Stevenson, L. Jeys et al.
Notes: Improves outcomes
Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative. BJS 2018; 105: e158-e168.
Authors: L. Rydén, N. Loman, C. Larsson, C. Hegardt, J. Vallon‐Christersson, M. Malmberg et al.
Notes: Promising Swedish initiative
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Authors: P. McAnena, A. Lowery, M. J. Kerin
Notes: Promising technology
MiR‐128 regulation of glucose metabolism and cell proliferation in triple‐negative breast cancer. BJS 2018; 105: 75-85.
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Notes: New molecular target?
International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction. BJS 2018; 105: 209-222.
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
Notes: Useful tool
Axillary tumour burden in women with a fine‐needle aspiration/core biopsy‐proven positive node on ultrasonography compared to women with a positive sentinel node. BJS 2017; 104: 1811-1815.
Authors: P. Lloyd, E. Theophilidou, R. G. Newcombe, L. Pugh, A. Goyal
Notes: Axillary ultrasound can detect low‐volume metastases
Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. BJS 2017; 104: 1675-1685.
Authors: A. Karakatsanis, K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson et al.
Notes: Simplifies logistics
Authors: M. Ahmed, M. Douek
Risk of death from breast cancer after treatment for ductal carcinoma in situ. BJS 2017; 104: 1506-1513.
Authors: C. Wadsten, H. Garmo, I. Fredriksson, M. Sund, F. Wärnberg
Notes: Rare, but worse for large tumours and uncertain margins
Improved prognosis of young patients with breast cancer undergoing breast‐conserving surgery. BJS 2017; 104: 1802-1810.
Authors: E. Botteri, P. Veronesi, J. Vila, N. Rotmensz, V. Galimberti, M. V. Thomazini et al.
Notes: Molecular subtype matters most